1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.

Slides:



Advertisements
Similar presentations
HEART TRANSPLANTATION
Advertisements

Changes in graft function in long term renal transplant recipients – analysis by CKD stage and recipient characteristics U.P.Udayaraj, D.Ansell, R.Steenkamp,
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:
Dialysis vs Transplant: the Australia & New Zealand experience Stephen McDonald ANZDATA Registry Adelaide, South Australia.
This Power Point presentation belongs to the Danish Renal Registry, which owns the copyright. It can be freely used for non-commercial study and educational.
Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients Deirdre Sawinski MD, Kimberly A.
Recent management of Renal Transplantation in a Developing Country like Bangladesh, R Alam, Islam M S, R Alam, H Rahman, HU Rashid Department of Nephrology,
Extracorporeal Membrane Oxygenation Following Lung Transplantation in Adult ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor.
USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.
Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.
HEART-LUNG TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
© ANZOD Registry Australian States Number of Donors Per Million Population Aust * NSW population excludes residents of the.
BWGHF Liège Heart transplantation 2008.
Allocation of deceased donor kidneys Phil Clayton NSW Renal Group 14 June 2012.
Monitoring HLA-specific antibodies
© ANZDATA Registry Method and Location of Dialysis 1453 (30%) 632 (13%) 1317 (27%) 1335 (27%) Number of Patients Australia 31-Dec-96.
INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
Why don’t indigenous dialysis patients receive transplants – waitlist or allocation? N. Khanal 1, P. Clayton 1, S. McDonald 1, M. Jose 2 1 The University.
Haemodialysis Vascular Access: Recent Trends From ANZDATA Dr Kevan Polkinghorne Monash Medical Centre ANZSN September 2007.
The Expanded Criteria Donors in Kidney Transplantation: 3 Years Experience FAM Shaheen, B. Al-Attar, MZ Souqiyyeh, J.E Cillo, A. Al Sayyari.
Factors Affecting Long-term First Renal Graft Survival Identified in a 10-year, 5-centre Retrospective National Study James Medcalf, John Bankart and Julie.
TRANSPLANTATION CHAPTER 8 ANZDATA Registry Annual Report 2013.
Transplantation in the Diabetic Patient The Status of Pancreas transplantation A. Osama Gaber Professor of Surgery Director of the Transplant Institute,
ANZDATA Registry Overview Dr Graeme Russ Darwin September 2001 September 2001.
A Comparison of Sevelamer and Calcium-Based Phosphate Binders on Mortality, Hospitalization, and Morbidity in Hemodialysis: A Secondary Analysis of the.
Chapter 11 Paediatrics 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Paediatric.
Chapter 10 Cancer 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013 ANZDATA gratefully acknowledges the contributions of the Cancer Working.
Chapter 12 End Stage Kidney Disease among Indigenous Peoples of Australia and New Zealand 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013.
HEART-LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
Chapter 6 Home Dialysis 2014 ANZDATA Registry 37th Annual Report Data to 31-Dec-2013.
An audit of CMV disease in renal transplant recipients transplanted at the Queen Elizabeth Hospital Birmingham Gemma Banham, Shazia Shabir, Richard Borrows.
Obesity in kidney transplantation…. Dan Ridgway, Consultant Surgeon, Royal Liverpool University Hospital.
Histological markers of CNI nephrotoxicity: Specific or not specific? Marion Rabant MD, Renaud Snanoudj MD, Virginie Royal MD, C. Girardin, E.Morelon MD.
HEART-LUNG TRANSPLANTATION Pediatric Recipients 2015 JHLT Oct; 34(10):
Quebec experience from 2003 to 2009 M Carrier MD, JF Lize MD and Quebec transplant programs Impact of Expanded Criteria Donors on outcomes of recipients.
What happens to patients returning to dialysis after transplant failure? Data from the UK Renal Registry Dr Lynsey Webb 1, Dr Anna Casula 1, Dr Charlie.
END-STAGE KIDNEY DISEASE AMONG INDIGENOUS PEOPLES OF AUSTRALIA AND NEW ZEALAND CHAPTER 12.
Impact of Recipient and Donor Non-immunological factors on the Outcome of Expanded Criteria Deceased Donors Kidney Transplantation Dr Hajar Al Hayyan.
Thymoglobulin: An Overview of Its Performance in Clinical Trials as an Agent for the Induction Therapy Reference: Osama Gaber A, Knight RJ, Patel S, et.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.
New kidney offering scheme … Lorna Marson Deputy Chair, Kidney Advisory Group Work in progress.
STUDY OF THE RISK FACTORS OF ACUTE REJECTION AFTER LIVE DONOR RENAL TRANSPLANTATION:A SINGLE EGYPTIAN CENTER EXPERIENCE Ayman M Nagib¹, Ahmed S Elsaied¹,
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Preemptive Kidney Transplant (PKT) – the Optimal Therapy in ESRD Reference: Connie L. Davis. Preemptive transplantation and the transplant first initiative.
The significance of Focal C4d+: The WU experience Helen Liapis, M.D. Professor of Pathology & immunology Kedainis RL et al. Am J Transplant Apr;9(4):812-9.
Kidney Graft Survival Rates do not improve by era: the impact of factor “Age” E. Bertoni MD, A. Larti MD, G. Rosso MD and M. Salvadori MD Renal Unit –
Obesity in the end stage kidney disease population
ANZDATA Epidemiology Fellow
The ALERT Trial.
Method Background Result Conclusion
ASSOCIATION OF SOCIO-ECONOMIC POSITION WITH TECHNIQUE FAILURE AND MORTALITY IN AUSTRALIAN NON-INDIGENOUS PERITONEAL DIALYSIS PATIENTS Dr Samuel Chan Nephrology.
Enterprise | Interest Nothing to disclose.
Number of Grafts Performed by Country
Liver only transplants in the UK Question 2: In terms of survival benefit.
ANZDATA Registry Annual Report 2013
Stephen P. McDonald  Kidney International Supplements 
Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor
ANZDATA Registry 41st Annual Report Highlights of End Stage Kidney Disease in Australia and New Zealand Data to 31-Dec-2017.
Stephen P. Mcdonald, Graeme R. Russ  Kidney International 
Volume 71, Issue 12, Pages (June 2007)
Update from the Haemodialysis Working Group
Pregnancy outcomes in kidney transplant recipients
Deceased solid organ donors Recent trends from ANZOD
Dialysis outcomes in Australia & New Zealand
Demographic Characteristics of Cohort
Acute Rejection in ANZ TSANZ 2003
Presentation transcript:

1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient risk factors and the choice of immunosuppression TH Mathew, SP McDonald & GR Russ ANZDATA Registry & Renal Unit, The Queen Elizabeth Hospital Adelaide. September, 2001

Source of data – ANZDATA & ANZOD Australia & New Zealand Dialysis & Transplant (ANZDATA) Registry –A voluntary registry documenting the outcome of all dialysis & transplant patients in Aus & NZ since 1965 –100% reporting and follow-up of ~24,000 patients Australia & New Zealand Organ Donor (ANZOD) Registry – Has acquired donor information since 1988 Registries co-located

Long term outcome in renal transplantation The short term (1yr) outcome has improved substantially in recent times The long term outcome beyond 5 yrs has been little studied This study aims to assess the influence of various factors on long term graft (& patient outcome) All data is from ANZDATA and ANZOD Registries.

Australia CD1. One year survival

Predictive patient & donor characteristics significantly affecting 1yr survival on multivariate analysis (0n cohort) – Briganti et al Donor agep=0.000 HLA mismatchesp=0.000 Vascular diseasep=0.002 Time on dialysisp=0.004 Year of transplantp=0.008 Allograft sourcep=0.044

Long term outcome in renal transplantation The short term (1yr) outcome has improved substantially in recent times The long term outcome in CD1 & LD1 recipients beyond 5 yrs has been little studied This study aims to assess the influence of various factors on long term graft (& patient outcome)

Australia primary patient & graft (CD & LD) survival n = 7623 grafts

Australia primary graft (CD & LD) survival n = 7623 grafts. The decay is exponential.

Australia primary graft survival n = 7623 grafts 1.8%/yr 2.7%/yr

5 Yr+ survival for primary grafts (n= 4353) Australia ( ) 4.3%/yr 3.2%/yr

Patient survival after 5 yrs (Aus CD1 & LD1) by selected time periods – the death rate has declined ~ %/yr

The death rate/100 patient years for primary renal grafts beyond 5 yrs is reducing in recent years

Death rate/100 patient years >5yrs post graft Australia CD1 & LD1 by period

Graft survival beyond 5 yrs (Aus CD1 & LD1). The decline is the same in each selected time period 4.8%/yr

Death censored graft fail rate/100 graft/yrs > 5yrs post has increased 33% since 1984 CD1& LD1 Australia

Cause of graft failure rate The loss from ‘chronic rejection’ is increased in recent times

Predictive characteristics favoring primary graft survival beyond 5yrs Significant factors on univariate analysis Donor source LDp= Donor age <50yrp= Donor not ‘marginal’ p=0.002 Donor death traumap=0.02 Recipient never smokedp= Not on CsA at 2 & 5yrs.P=0.0004

Predictive characteristics favoring primary graft survival beyond 5yrs Non –significant factors on univariate analysis Donor hypertensive Donor oliguric Donor terminal creatinine >120umol/l Donor smoked CsA dose >5mg/kg/d Primary renal disease Use of Ab for rejection in 1 st 6m Delayed graft function >7d

Effect of donor source on graft outcome >5yrs ( Aus CD – 2646 grafts) p < %/yr 4%/yr

Effect of donor age on graft outcome >5yrs ( Aus CD – 2646 grafts) p < %/yr 4.7%/yr

Effect of recipient smoking on graft outcome >5yrs ( Aus CD – 2646 grafts) p < (former v never) 7.8%/yr 7%/yr 5.4%/yr

Graft survival on CsA is reduced >5yrs (Aus CD1 & LD1 n=4009) 3.8%/yr 5.3%/yr p <0.0000

Graft survival (death censored) 5yrs + CsA & no CsA ( Aus CD1 & LD1) 3.4%/yr 2.1%/yr p <0.0000

Predictive characteristics favoring primary graft survival beyond 5yrs Significant factors on univariate analysis Donor source LD*p= Donor age <50yr*p= Donor not ‘marginal’ p=0.002 Recipient never smoked*p= Donor death traumap=0.02 Not on CsA at 2 & 5yrs *p = * Retained significance on multivariant analysis

Multivariate analysis of factors affecting death censored primary graft outcome >5yrs Significant factors HR(CI) On CsA1.9( ) Recipient smoking1.86( ) Recipient <20yrs1.55( ) Donor Age >50yrs1.51( ) Recipient >50yrs0.61( ) Live donor0.67( )

Multivariate analysis of factors affecting death censored primary graft outcome >5yrs Non -Significant factors Mismatch on HLA Marginal donor status Vascular disease at entry Year of transplant Cause of donor death

The effect of CsA on long term graft (death censored) outcome Is statistically and clinically significant : - –10% difference over ten yrs –Most evident in those with S Cr <140umol/L at 1 yr Not accounted for by –donor source or quality –vascular disease pre entry The patients on CsA had –worse matching (-) –more recipients >50yrs (+) –more marginal donors (-) –more smokers (-) (all marginally significant)

European Multicenter trial (Transpl Proc 25:527, 1993) Data redrawn with 5yr survival adjusted to 100%. (ITT) 4%/yr 2.2%/yr

Conclusions on graft loss beyond 5 years Grafts fail after 5 years through 1. Death. The death rate is currently decreasing & now accounts for 48% of losses 2.Graft failure. The rate of loss is increasing due to an increase in ‘chronic rejection’ & ‘other’ causes Increased risk of late graft loss (death censored) with –Continuing exposure to CsA, donor age >50yrs, recipient age <20yrs, recipient smoking Decreased risk of late graft loss (death censored) with –Recipients >50yrs, live donors